The industrial and services robot market are expected to grow at over `18% to be a $176 billion market in 2025. Numerous engines are expected to fuel its growth – A.I in Robotics, Cloud Robotics, Connected Autonomous Systems, Enterprise Robotic Automation, COBOTS, Biorobotics, Exoskeletons, Biped and Humanoids, Unmanned Aerial Systems, Advanced Vision Systems, Implantable sensors for Robotics as well as others.
A host of attractive, high growth opportunities such as Smart Factory, Precision Agriculture, Last Mile Delivery, Warehouse Automation, Cooperative & Network Robotics, Entertainment Robotics, Robotics in industrial monitoring, IOT/Industry 4.0 etc could be pursued. Participants such as system integrators, OEMs, Software and Programming vendors, End of Arm tool manufacturers, Drives and control system providers etc can benefit from this unprecedented growth over the next 5 years.
This Crystal Ball event focuses on learning more about the most promising opportunities in the Robotics ecosystem, as seen through the lens of eminent CXOs in this space.
The Artificial Intelligence (AI) market is expected to grow at over `36% to be a $190 Bn market in 2025. Numerous engines are expected to fuel its growth – increase in amount of big data, increased adoption of cloud-based applications and services, increase in demand for virtual assistants, emergence of new use cases as well as others.
From computer vision systems and predictive analytics improving manufacturing operations to self-learning algorithms that help us make better decisions, the AI/ML algorithms will continue to evolve and provide a host of attractive, high growth opportunities. Participants such as CIOs, CTOs, CMOs, AI hardware providers, AI solution and service providers, automation technology providers etc can benefit from this unprecedented growth over the next 5 years.
This Crystal Ball event focuses on learning more about the most promising opportunities in the AI space, as seen through the lens of eminent CXOs in this space.
The end product sales in bioproduction market are expected to grow at over `15% to be a $305 Bn market in 2025. Numerous engines are expected to fuel its growth – Cell Therapy, Gene Therapy, Monoclonal Antibodies, Vaccines, biosimilars and biobetters, plasma therapy as well as others.
A host of attractive, high growth opportunities such as single use systems, Lab Scale and CGMP manufacturing and R&D, Crispr and other Gene editing tools and technologies, Novel downstream bioprocessing methods etc could be pursued. Participants such as CROs, CMOs, Bioprocess solutions manufacturers, Biobanks, automation technology providers etc can benefit from this unprecedented growth over the next 5 years.
This Crystal Ball event focuses on learning more about the most promising opportunities in the Bioproduction ecosystem, as seen through the lens of eminent CXOs in this space
Digital Transformation has accelerated immensely in the past few months, Fintech and Blockchain are at the center of this paradigm shift from Traditional Banking to Digital Banking. With the Financial Services and Banking sector bracing themselves for uncertain times, the industries have witnessed advanced innovations, larger investments, and greater productivity. This has led to a rise of Fintech and Blockchain Technology in the Middle East to adopt the changing economy trends.
One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations.
Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer. Globally, there is a significant growth in the incidence of cancer. Diseases like musculoskeletal diseases, glaucoma, and specifically cancer have a significant impact on the health status of people worldwide, with comparatively higher growth rates in developing countries.
Technological innovation influences mission-critical applications in business processes and the manufacturing and technology companies that take the risk and are early adopters of new technology will be rewarded for their progressive decision-making. Since, digitization helps to ensure product quality and safety, as well as faster service delivery, it ensures to go a long way with customers. This has made the IoT adaptation the need of hour!
The 8th Edition Biomarker and Companion Diagnostics Virtual Conference scheduled to be held on 25 - 26 March 2021 would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data.
Based on the survey on 1,000 hospitals in 33 countries, European Centre for Disease Prevention and Control (ECDC) estimates that that on any given day, one in 18 patients in a European hospital has healthcare-associated infection (HAIs). Most the countries (26 out of 33) reported the major three types of HAIs: pneumonia and lower respiratory tract infection, surgical site infection and urinary tract infection.
COVID-19 has changed the business landscape for everyone. In these constantly evolving and changing times, it is essential for business organizations to stay ahead of time and create newer strategies to optimize revenue. Disruptive innovative technologies are now being introduced to overcome challenging times. To gain competitive advantage, businesses must incorporate these technologies along with long-term strategies into their business models.
As per MarketsandMarkets research analysis, the global dPCR and qPCR is estimated to grow to USD 6,270.9 million by 2024 at a CAGR of 8.8%. Factors such as the rising incidences of target infectious diseases and genetic disorders; continuous technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of this market. However, the high instrument costs—especially that of dPCR—and the technical limitations of PCR have restricted their greater use.
MarketsandMarkets is proud to announce the 4th Annual MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference to be held on 22- 23 April, 2021.
While the 3rd annual virtual conference had discussions on how the insights derived from real world data, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators, doctors, and payers, the 4th Annual conference will focus on discussion about the application of RWD/RWE across the life cycle. The event will discuss Impact of COVID-19 on the real-world generation and making sense of the Electronic Health Records data for COVID-19.
5G is paving the way in many smart opportunities and is revolutionizing the technology world. Breakthrough technologies for the 5G deployment and infrastructure are going to change the game.
The conference is focused on few of the major questions such as what is the Influence of ML and AI on 5G? The privacy and security risk? How to tap into 5G monetization opportunity? Understanding business implications of booming trends of 5G
After the successful foureditions of Bioprocessing of Cell therapies, coming up with 5th Annual of Bioprocessing of Biotherapeutics brings together leading bioprocessing scientists to share day-to-day challenges and practical solutions for the development, manufacture and quality of protein expressions, cell, and gene therapies.
The virtual event will present detailed case studies and interactive discussions in cell culture, scale-up, continuous processing, recovery, purification, process and product characterization, and formulation.
Digitization, growing robotics, and modern business models have revolutionized most sectors, especially the automotive industry. Linked cars with automatic piloting have forced the digitalisation of the automotive industry, showing the undeniable value of data in automotive market.
Growing interest in 3D printing in the automotive industry, starting from the possibility of fast prototyping, this technology is proving vital role in the industry.
Technology and creativity continue to alter the working environment. Consumer demands are becoming more challenging every day, and keeping up with trends can be overwhelming. Today's leadership of the CMO is about promoting growth, and their responsibility for sales and marketing strategies that needed to meet business acumen is utmost challenging
Pharmaceutical supply chain and logistics faced the hardest disruptions during initial COVID era. Now, with COVID therapeutic manufacturing taking priority, there also is a big desire to accelerate other clinical pipeline because of the ample opportunity for new medicine. While some companies were able to cope with their contingencies plan in place, the other followed risk mitigation. It is now essential for the pharma supply chain and logistics to follow the redundancy routes.
Technology, digitization, and globalization are disrupting conventional business models. The design and customer experience functions are witnessing an exponential shift. Design Thinking helps enable the integration of technology with a human centered approach into the business strategy. Conceived with a vision to promote a knowledge sharing and networking platform, the 2nd Edition MarketsandMarkets Design Thinking Virtual Summit, scheduled to be held on 16th-17th June
Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress-US Edition to be held on 28th-30th June 2021 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.
The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.